Abstract
In the global, Phase 3 HIMALAYA study (NCT03298451) in uHCC, a single priming dose of T plus regular interval D (STRIDE) significantly improved overall survival (OS) vs sorafenib (S), and D was noninferior to S (Abou-Alfa et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2100070). HCC aetiology varies globally and may influence response to immunotherapy. HBV is predominant in most Asian countries, whereas HCV or nonviral aetiologies are more common in Japan and Western countries. Thus, we analysed outcomes in patients (pts) enrolled in Asia, excluding Japan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
